ATYR

aTyr Pharma

2.88 USD
-0.14
4.64%
At close Apr 1, 4:00 PM EDT
After hours
3.00
+0.12
4.17%
1 day
-4.64%
5 days
-17.71%
1 month
-12.73%
3 months
-26.34%
6 months
67.44%
Year to date
-26.34%
1 year
50.79%
5 years
12.94%
10 years
-98.62%
 

About: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Employees: 59

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

329% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 7

136% more capital invested

Capital invested by funds: $84.3M [Q3] → $199M (+$114M) [Q4]

100% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 12

40% more funds holding

Funds holding: 55 [Q3] → 77 (+22) [Q4]

2.21% more ownership

Funds ownership: 63.17% [Q3] → 65.38% (+2.21%) [Q4]

18% less call options, than puts

Call options by funds: $195K | Put options by funds: $237K

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$16
456%
upside
Avg. target
$26
785%
upside
High target
$35
1,115%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
20% 1-year accuracy
85 / 422 met price target
1,115%upside
$35
Buy
Reiterated
14 Mar 2025
Leerink Partners
Faisal Khurshid
17% 1-year accuracy
2 / 12 met price target
456%upside
$16
Outperform
Initiated
18 Feb 2025

Financial journalist opinion

Based on 9 articles about ATYR published over the past 30 days

Neutral
GlobeNewsWire
5 days ago
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors approved on March 21, 2025 an aggregate of three grants to three employees of nonstatutory stock options to purchase an aggregate of 43,800 shares of aTyr's common stock with a weighted-average exercise price of $3.69 per share, which is equal to the weighted-average closing price of aTyr's common stock on the Nasdaq Capital Market on the effective dates of the grants. These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
6 days ago
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise.
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
Positive
Zacks Investment Research
1 week ago
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
Here is how Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
Positive
Seeking Alpha
2 weeks ago
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating
aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows promise in reducing fibrosis without immunosuppression, with recent safety data and a peer-reviewed publication bolstering confidence in its efficacy. Institutional ownership has surged to nearly 80%, indicating strong institutional confidence despite the inherent risks associated with earlier trial failures.
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating
Neutral
Seeking Alpha
2 weeks ago
aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript
aTyr Pharma, Inc. (NASDAQ:ATYR ) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Ashlee Dunston - Senior Director of Investor Relations and Public Affairs Sanjay Shukla - President and Chief Executive Officer Leslie Nangle - Vice President of Research Jill Broadfoot - Chief Financial Officer Conference Call Participants Derek Archila - Wells Fargo & Company Yasmeen Rahimi - Piper Sandler Companies Faisal Khurshid - Leerink Partners LLC Prakhar Agrawal - Cantor Fitzgerald, L.P. Gregory Renza - RBC Capital Markets Joe Pantginis - H.C.
aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 weeks ago
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile.
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Neutral
GlobeNewsWire
2 weeks ago
aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine
Peer-reviewed publication validates efzofitimod's unique anti-inflammatory mechanism of action on macrophages through neuropilin-2 (NRP2) receptor. Scientific insights further strengthen the rationale for clinical program for efzofitimod in interstitial lung disease (ILD).
aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine
Neutral
GlobeNewsWire
3 weeks ago
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the outcome of a fourth, pre-planned interim safety analysis conducted by an independent data and safety monitoring board (DSMB) for the ongoing Phase 3 EFZO-FIT™ study of the Company's lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis. The DSMB recommended that the study continue without any modifications.
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Neutral
GlobeNewsWire
4 weeks ago
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2024 financial results and provide a corporate update after the market close on Thursday, March 13, 2025. Management will host a conference call and webcast to review the results and provide an operational update.
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
Neutral
GlobeNewsWire
1 month ago
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
Charts implemented using Lightweight Charts™